Login to Your Account



Oncogenex: Pancreatic miss doesn't dim hopes for apatorsen program

By Jennifer Boggs
Managing Editor

Wednesday, September 23, 2015

With multiple midstage trials ongoing of apatorsen in several cancer types, Oncogenex Pharmaceuticals Inc. is unlikely to spend too much time ruminating on the failure of the phase II Ranier trial testing the drug, formerly known as OGX-427, in pancreatic cancer, an arguably long-shot indication from the start.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription